Acumen Pharmaceuticals (ABOS) Retained Earnings (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Retained Earnings of $21000.0 in Q1 2026, up 100.0% quarter-over-quarter from -$446.5 million in Q4 2025, and up 100.01% year-over-year from $10499.7 in Q1 2025.
Acumen Pharmaceuticals' Retained Earnings history runs 7 years deep, the most recent figure standing at $21000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 100.01% year-over-year to $21000.0; the TTM figure through Mar 2026 stood at $21000.0 (up 100.01% YoY), while the FY2025 annual figure was -$446.5 million, down 930029.17% from the prior year.
- Retained Earnings came in at $21000.0 for Q1 2026 at Acumen Pharmaceuticals, up from -$446.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $518000.0 in Q3 2024 to a low of -$446.5 million in Q4 2025.
- A 5-year average of -$184.4 million and a median of -$181.7 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings surged 141.54% in 2023 and sank 930029.17% in 2025, its largest moves.
- Acumen Pharmaceuticals' Retained Earnings stood at -$751000.0 in 2022, then soared by 141.54% to $312000.0 in 2023, then slumped by 115.38% to -$48000.0 in 2024, then tumbled by 930029.17% to -$446.5 million in 2025, then soared by 100.0% to $21000.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $21000.0, -$446.5 million, and -$421.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21,000.00 |
| Dec 31, 2025 | -446.46 Mn |
| Sep 30, 2025 | -421.32 Mn |
| Jun 30, 2025 | -394.87 Mn |
| Mar 31, 2025 | -353.90 Mn |
| Dec 31, 2024 | -48,000.00 |
| Sep 30, 2024 | 518,000.00 |
| Jun 30, 2024 | -258.20 Mn |
| Mar 31, 2024 | -237.67 Mn |
| Dec 31, 2023 | 312,000.00 |
| Sep 30, 2023 | -206.30 Mn |
| Jun 30, 2023 | -193.30 Mn |
| Mar 31, 2023 | -181.70 Mn |
| Dec 31, 2022 | -751,000.00 |
| Sep 30, 2022 | -157.56 Mn |
| Jun 30, 2022 | -146.85 Mn |
| Mar 31, 2022 | -136.70 Mn |
| Dec 31, 2021 | -127.57 Mn |
| Sep 30, 2021 | -119.20 Mn |
| Jun 30, 2021 | -115.32 Mn |
| Dec 31, 2020 | -27.00 Mn |